Clinical trial
An Exploratory Clinical Trial Evaluating LX109 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD)
NCT06022744 is registered in ClinicalTrials.gov with Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Exploratory Clinical Trial Evaluating LX109 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD)
- Lead sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- September 1, 2023
- Completion date
- September 30, 2027
- Enrollment
- 12 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
to evaluate the safety and tolerability of intravitreal injection of lx109 in patients with namd